RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+14.7%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$5.47B
AUM Growth
+$5.47B
(+6.5%)
Cap. Flow
+$466M
Cap. Flow
% of AUM
8.53%
Top 10 Holdings %
Top 10 Hldgs %
51.96%
Holding
75
New
18
Increased
7
Reduced
14
Closed
5
Top Buys
| 1 |
Nkarta
NKTX
|
$168M |
| 2 |
Ascendis Pharma
ASND
|
$154M |
| 3 |
Seres Therapeutics
MCRB
|
$134M |
| 4 |
iTeos Therapeutics
ITOS
|
$109M |
| 5 |
VXRT
Vaxart
VXRT
|
$71.9M |
Top Sells
| 1 |
Novavax
NVAX
|
$386M |
| 2 |
TG Therapeutics
TGTX
|
$106M |
| 3 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
$84.2M |
| 4 |
Stoke Therapeutics
STOK
|
$26.7M |
| 5 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$25.3M |
Sector Composition
| 1 | Healthcare | 93.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ascendis Pharma
ASND
$11.8B
| $912M | 16.68% | 5,909,742 +994,787 | +20% | +$154M |
|
|
FMTX
2
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $449M | 8.22% | 9,011,651 | – | – |
|
|
CCXI
3
DELISTED
ChemoCentryx, Inc.
CCXI
| $265M | 4.84% | 4,826,910 | – | – |
|
4
Vaxcyte
PCVX
$4B
| $261M | 4.77% | 5,283,818 -205,363 | -4% | -$10.1M |
|
|
5
TG Therapeutics
TGTX
$4.65B
| $236M | 4.32% | 8,825,849 -3,962,608 | -31% | -$106M |
|
|
6
Nkarta
NKTX
$151M
| $168M | 3.08% | +5,605,129 | New | +$168M |
|
7
Axsome Therapeutics
AXSM
$6.05B
| $145M | 2.65% | 2,035,132 | – | – |
|
8
Phathom Pharmaceuticals
PHAT
$864M
| $140M | 2.57% | 3,825,008 | – | – |
|
|
9
Seres Therapeutics
MCRB
$166M
| $134M | 2.46% | +4,750,000 | New | +$134M |
|
|
10
Novavax
NVAX
$1.21B
| $130M | 2.38% | 1,198,602 -3,560,231 | -75% | -$386M |
|
11
89bio
ETNB
$1.34B
| $122M | 2.22% | 4,736,214 +1,575,000 | +50% | +$40.4M |
|
12
Rhythm Pharmaceuticals
RYTM
$6.85B
| $111M | 2.04% | 5,140,408 -69,680 | -1% | -$1.51M |
|
13
MacroGenics
MGNX
$112M
| $110M | 2.02% | 4,375,217 -209,435 | -5% | -$5.28M |
|
|
EIDX
14
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $109M | 2% | 2,163,271 +600 | +0% | +$30.3K |
|
|
15
iTeos Therapeutics
ITOS
| $109M | 1.99% | +4,417,258 | New | +$109M |
|
|
ZGNX
16
DELISTED
Zogenix, Inc.
ZGNX
| $98.4M | 1.8% | 5,488,424 +1,811,000 | +49% | +$32.5M |
|
17
Adverum Biotechnologies
ADVM
$64.6M
| $96.9M | 1.77% | 9,410,860 +1,609,219 | +21% | +$16.6M |
|
|
ADAP
18
Adaptimmune Therapeutics
ADAP
$15.6M
| $90.4M | 1.65% | 11,329,581 -1,722,883 | -13% | -$13.7M |
|
|
TRIL
19
DELISTED
Trillium Therapeutics Inc.
TRIL
| $87.6M | 1.6% | 6,162,694 | – | – |
|
20
Arvinas
ARVN
$568M
| $86.7M | 1.59% | 3,672,872 | – | – |
|
21
Travere Therapeutics
TVTX
$1.56B
| $85.6M | 1.57% | 4,635,687 | – | – |
|
22
KALA BIO
KALA
$78.8M
| $81.6M | 1.49% | 10,874,613 | – | – |
|
23
Black Diamond Therapeutics
BDTX
$157M
| $78.3M | 1.43% | 2,589,904 | – | – |
|
24
Legend Biotech
LEGN
$6.41B
| $74.3M | 1.36% | 2,408,292 -73,650 | -3% | -$2.27M |
|
|
IGMS
25
DELISTED
IGM Biosciences
IGMS
| $72.5M | 1.33% | 982,723 | – | – |
|